Parenteral Fish‑Oil Lipid Emulsions in Retinopathy of Prematurity: A Retrospective Comparative Study

Purpose: To evaluate the effects of a fish oil‑containing regimen on the severity of retinopathy of prematurity (ROP) in preterm infants. Methods: In this retrospective, observational study, 82 preterm infants with documented retinal examinations were evaluated. Patients’ demographic data, associated morbidities, the worst ROP zone, stage, and the presence of plus disease during the follow‑up examinations, and the need for ROP treatment in the two groups were recorded and analyzed. Results: Forty‑three infants were treated with INTRAlipid®, and 39 infants were treated with 20% SMOFlipid. There were no differences in gestational age, birth weight, and associated morbidities between the two groups. No differences were observed among the two groups in their need for treatment (P = 0.51), ROP zones (P = 0.62), and plus disease (P = 0.38). Although no difference was seen in ROP stages between the groups (P = 0.41), in subgroup analysis, Stage 3 (severe ROP) occurred significantly lower in the SMOFlipid group (P = 0.04) and Stage 0 occurred significantly higher in the SMOFlipid‑treated infants (P = 0.05). Conclusions: This study showed no difference between the two groups regarding the need for the treatment. The lower prevalence of severe ROP in preterm infants receiving SMOFlipid emulsion was observed comparing to the INTRAlipid‑treated infants